Les traitements cibles dans l'asthme: confirmations, espoirs et deceptions.

Anti-Asthmatic Agents/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Asthma/drug therapy; Humans; Immunoglobulin E/immunology; Interleukins/antagonists & inhibitors; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Abstract :

[en] Asthma is a chronic inflammatory disease of the airways. The inflammatory process is driven by different pathways involving cytokines and other protein mediators. Patients with severe asthma are at high risk of severe exacerbations and death and have few therapeutic options available. Therefore, biological agents have been developed to help patients with refractory asthma by interfering with several compounds of the asthma inflammatory cascade. In addition to decreasing exacerbations, some of those treatments have a steroid sparing role and many beneficial effects in asthmatics.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

SCHLEICH, FLorence

LOUIS, Renaud ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

Language :

French

Title :

Les traitements cibles dans l'asthme: confirmations, espoirs et deceptions.

Alternative titles :

[en] Targeted asthma therapies: confirmations, hopes, and disappointments

Publication date :

2012

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

67 Spec No

Pages :

14-21

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be/

Available on ORBi :

since 07 November 2012

Statistics

Number of views

222 (11 by ULiège)

Number of downloads

993 (13 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Bateman ED, Boushey HA, Bousquet J, et al. - Can guideline- defined asthma control be achieved ? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med, 2004, 170, 836-844. (Pubitemid 39346477)
Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med, 2000, 162, 2341-2351.
Godard P, Chanez P, Siraudin L, et al. - Costs of asthma are correlated with severity : a 1-yr prospective study. Eur Respir J, 2002, 19, 61-67. (Pubitemid 34105569)
Bousquet J, Boulet LP, Peters MJ, et al. - Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med, 2007, 101, 2437-2446. (Pubitemid 350010579)
Wenzel SE, Szefler SJ, Leung DY, et al. - Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med, 1997, 156, 737-743. (Pubitemid 27396409)
Quaedvlieg V, Sele J, Henket M, Louis R. - Association between asthma control and bronchial hyperresponsiveness and airways inflammation : a cross-sectional study in daily practice. Clin Exp Allergy, 2009, 39, 1822-1829.
Romagnoli M, Vachier I, Tarodo dlF, et al. - Eosinophilic inflammation in sputum of poorly controlled asthmatics. Eur Respir J, 2002, 20, 1370-1377. (Pubitemid 35460603)
Lemiere C, Ernst P, Olivenstein R, et al. - Airway inflammation assessed by invasive and noninvasive means in severe asthma : eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol, 2006, 118, 1033-1039. (Pubitemid 44666987)
Burrows B, Martinez FD, Halonen M, et al. - Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med, 1989, 320, 271-277. (Pubitemid 19045550)
Kitaura J, Song J, Tsai M, et al. - Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci USA, 2003, 100, 12911-12916. (Pubitemid 37339999)
Takatsu K, Nakajima H. - IL-5 and eosinophilia. Curr Opin Immunol, 2008, 20, 288-294.
Motojima S, Akutsu I, Fukuda T, et al. - Clinical significance of measuring levels of sputum and serum ECP and serum IL-5 in bronchial asthma. Allergy, 1993, 48, 98-106. (Pubitemid 24036220)
Robinson DS, Hamid Q, Ying S, et al. - Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med, 1992, 326, 298-304.
Coffman RL, Ohara J, Bond MW, et al. - B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide- activated B cells. J Immunol, 1986, 136, 4538-4541. (Pubitemid 16090673)
Oh CK, Geba GP, Molfino N. - Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev, 2010, 19, 46-54.
Hsieh FH, Lam BK, Penrose JF, et al. - T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells : profound induction of leukotriene C(4) synthase expression by interleukin 4. J Exp Med, 2001, 193, 123-133.
Bettiol J, Sele J, Henket M, et al.- Cytokine production from sputum cells after allergenic challenge in IgE-mediated asthma. Allergy, 2002, 57, 1145-1150.
Brightling CE, Saha S, Hollins F. - Interleukin-13: prospects for new treatments. Clin Exp Allergy, 2010, 40, 42-49.
Kraft M, Hamid Q, Chrousos GP, et al. - Decreased steroid responsiveness at night in nocturnal asthma. Is the macrophage responsible? Am J Respir Crit Care Med, 2001, 163, 1219-1225. (Pubitemid 32378463)
Spahn JD, Szefler SJ, Surs W, et al. - A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol, 1996, 157, 2654-2659. (Pubitemid 126450482)
Hughes JM, Stringer RS, Black JL, Armour CL. - The effects of tumour necrosis factor alpha on mediator release from human lung. Pulm Pharmacol, 1995, 8, 31-36.
Belaiche J, Louis E. - Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies. Rev Med Liege, 2000, 55, 827-832.
Thomas PS, Heywood G. - Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax, 2002, 57, 774-778. (Pubitemid 34984975)
Howarth PH, Babu KS, Arshad HS, et al. - Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax, 2005, 60, 1012-1018. (Pubitemid 41705469)
Manise M, Schleich F, Gusbin N, et al. - Cytokine production from sputum cells and blood leukocytes in asthmatics according to disease severity. Allergy, 2010, 65, 889-896.
Corrigan CJ, Hartnell A, Kay AB. - T lymphocyte activation in acute severe asthma. Lancet, 1988, 1, 1129-1132.
Park CS, Lee SM, Chung SW, et al. - Interleukin-2 and soluble interleukin-2 receptor in bronchoalveolar lavage fluid from patients with bronchial asthma. Chest, 1994, 106, 400-406.
Tarantini F, Baiardini I, Passalacqua G, et al. - Asthma treatment : 'magic bullets which seek their own targets'. Allergy, 2007, 62, 605-610. (Pubitemid 46763449)
Chang TW. - The pharmacological basis of anti-IgE therapy. Nat Biotechnol, 2000, 18, 157-162.
Owen CE. - Anti-immunoglobulin E therapy for asthma. Pulm Pharmacol Ther, 2002, 15, 417-424.
Corne J, Djukanovic R, Thomas L, et al. - The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects : efficacy, safety, and pharmacokinetics. J Clin Invest, 1997, 99, 879-887. (Pubitemid 27123624)
Hochhaus G, Brookman L, Fox H, et al. - Pharmacodynamics of omalizumab : implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin, 2003, 19, 491-498.
Fahy JV, Liu J, Wong H, Boushey HA.- Analysis of cellular and biochemical constituents of induced sputum after allergen challenge : a method for studying allergic airway inflammation. J Allergy Clin Immunol, 1994, 93, 1031-1039.
MacGlashan DW, Bochner BS, Adelman DC, et al.- Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol, 1997, 158, 1438-1445.
Humbert M, Beasley R, Ayres J, et al.- Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy, 2005, 60, 309-316.
Brusselle G, Michils A, Louis R, et al. - "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med, 2009, 103, 1633-1642.
Vignola AM, Humbert M, Bousquet J, et al. - Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis : SOLAR. Allergy, 2004, 59, 709-717. (Pubitemid 38850345)
Hanania NA, Alpan O, Hamilos DL, et al. - Omalizumab in severe allergic asthma inadequately controlled with standard therapy : a randomized trial. Ann Intern Med, 2011, 154, 573-582.
Busse W, Corren J, Lanier BQ, et al. - Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol, 2001, 108, 184-190. (Pubitemid 32735398)
Busse WW, Massanari M, Kianifard F, Geba GP. - Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma : a pooled analysis. Curr Med Res Opin, 2007, 23, 2379-2386. (Pubitemid 350033439)
Holgate ST, Chuchalin AG, Hebert J, et al. - Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy, 2004, 34, 632-638. (Pubitemid 38534897)
Louis R. - Anti-IgE : a significant breakthrough in the treatment of airway allergic diseases. Allergy, 2004, 59, 698-700. (Pubitemid 38850343)
Hamelmann E, Oshiba A, Loader J, et al. - Antiinterleukin- 5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am J Respir Crit Care Med, 1997, 155, 819-825. (Pubitemid 27133388)
Lach-Trifilieff E, McKay RA, Monia BP, et al. - In vitro and in vivo inhibition of interleukin (IL)-5-mediated eosinopoiesis by murine IL-5Ralpha antisense oligonucleotide. Am J Respir Cell Mol Biol, 2001, 24, 116-122. (Pubitemid 32152072)
Busse WW, Katial R, Gossage D, et al. - Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol, 2010, 125, 1237-1244.
Flood-Page P, Swenson C, Faiferman I, et al. - A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med, 2007, 176, 1062-1071. (Pubitemid 350223751)
Kips JC, O'Connor BJ, Langley SJ, et al. - Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma : a pilot study. Am J Respir Crit Care Med, 2003, 167, 1655-1659. (Pubitemid 36760679)
Leckie MJ, ten Brinke A, Khan J, et al. - Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet, 2000, 356, 2144-2148.
Haldar P, Brightling CE, Hargadon B, et al. - Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med, 2009, 360, 973-984.
Nair P, Pizzichini MM, Kjarsgaard M, et al. - Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med, 2009, 360, 985-993.
Castro M, Mathur S, Hargreave F, et al. - Reslizumab for poorly controlled, eosinophilic asthma : a randomized, placebo-controlled study. Am J Respir Crit Care Med, 2011, 184, 1125-1132.
Woodruff PG, Modrek B, Choy DF, et al. - T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med, 2009, 180, 388-395.
Corren J, Lemanske RF, Hanania NA, et al. - Lebrikizumab treatment in adults with asthma. N Engl J Med, 2011, 365, 1088-1098.
Wenzel S, Wilbraham D, Fuller R, et al. - Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients : results of two phase 2a studies. Lancet, 2007, 370, 1422-1431. (Pubitemid 47576168)
Erin EM, Leaker BR, Nicholson GC, et al. - The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med, 2006, 174, 753-762. (Pubitemid 44511656)
Berry MA, Hargadon B, Shelley M, et al. - Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med, 2006, 354, 697-708. (Pubitemid 43247140)
Morjaria JB, Chauhan AJ, Babu KS,et al. - The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma : a double blind, randomised, placebo controlled trial. Thorax, 2008, 63, 584-591. (Pubitemid 351969250)
Wenzel SE, Barnes PJ, Bleecker ER, et al. - A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med, 2009, 179, 549-558.
Holgate ST, Noonan M, Chanez P, et al. - Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J, 2011, 37, 1352-1359.
Busse WW, Israel E, Nelson HS, et al. - Daclizumab improves asthma control in patients with moderate to severe persistent asthma : a randomized, controlled trial. Am J Respir Crit Care Med, 2008, 178, 1002-1008.